Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoMARS: Dalpiciclib and Letrozole in Neoadjuvant Treatment of HR+/HER2- Breast Cancer
NCT06650748Phase 2Enrolling by invitation
- Sponsor
- Peking University
- Start
- May 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dalpiciclib in breast cancer (4 arms), sponsored by Peking University. Primary endpoint: Proportion of patients achieving PEPI score 0 and pathological Complete Response at 6 months. Started May 2025; status: enrolling by invitation.
02
Drugs
dalpiciclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06650748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06650748.